Protalix BioTherapeutics (PLX) EBITDA (2010 - 2026)

Protalix BioTherapeutics' EBITDA history runs 17 years deep, the most recent figure standing at $21.1 million for Q1 2026.

• On a quarterly basis, EBITDA rose 610.16% year-over-year to $21.1 million in Q1 2026; TTM through Mar 2026 was $19.8 million, a 327.64% increase from a year earlier, with the FY2025 full-year figure at -$5.5 million, down 240.41% from the prior year.
• EBITDA rose to $21.1 million in Q1 2026 per PLX's latest filing, from -$4.7 million in the prior quarter.
• Across five years, EBITDA topped out at $21.1 million in Q1 2026 and bottomed at -$5.6 million in Q4 2023.
• The 5-year median for EBITDA is -$2.4 million (2024), against an average of $1.0 million.
• Across the five-year window, EBITDA tumbled 164.61% in 2025 and soared 610.16% in 2026, its largest moves.
• Year by year, EBITDA stood at -$2.5 million in 2022, then sank by 125.05% to -$5.6 million in 2023, then jumped by 228.39% to $7.2 million in 2024, then tumbled by 164.61% to -$4.7 million in 2025, then jumped by 553.97% to $21.1 million in 2026.
• Per Business Quant, the three latest PLX EBITDA figures stand at $21.1 million (Q1 2026), -$4.7 million (Q4 2025), and $2.1 million (Q3 2025).